Neuropilin-1 and Neuropilin-2 form a small family of plasma membrane spanning receptors
originally identified by the binding of semaphorin and vascular endothelial growth factor …

Antibodies have proven their high value in antitumor therapy over the last two decades.
They are currently being used as the first-choice to treat some of the most frequent …

The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of
noninvasive and quantitative technologies capable of monitoring the presence and …

MPDL3280A is a human monoclonal antibody that targets programmed cell death-1 ligand 1
(PD-L1), and exerts anti-tumor activity mainly by blocking PD-L1 interaction with …

The noninvasive detection and quantification of CD8+ T cells in vivo are important for both
the detection and staging of CD8+ lymphomas and for the monitoring of successful cancer …

The blockade of tumour vascularisation and angiogenesis continues to be a focus for drug
development in oncology and other pathologies. Historically, targeting vascular endothelial …

Simple Summary The rapid development of diagnostic and therapeutic methods of the
cancer treatment causes that these diseases are becoming better known and the fight …

Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that acts as a co-receptor for various
members of the vascular endothelial growth factor (VEGF) family. Its ability to bind or …

Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers are treated
using targeted antibodies and kinase inhibitors, but resistance to these therapies leads to …

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by progressive
distal axonopathy that precedes actual motor neuron death. Triggers for neuromuscular …